CVE:ICO

iCo Therapeutics (ICO) Stock Price, News & Analysis

C$0.10
0.00 (0.00%)
(As of 03/19/2021)
Today's Range
C$0.10
C$0.11
50-Day Range
C$0.11
C$0.11
52-Week Range
C$0.02
C$0.16
Volume
1.31 million shs
Average Volume
3.16 million shs
Market Capitalization
C$951,825.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ICO stock logo

About iCo Therapeutics Stock (CVE:ICO)

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.

ICO Stock Price History

ICO Stock News Headlines

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.
Enlivex Therapeutics Ltd (ENLV)
See More Headlines
Receive ICO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iCo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.01 per share
Book Value
C$0.00 per share

Miscellaneous

Free Float
N/A
Market Cap
C$951,825.00
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. William Wasyl Jarosz (Age 65)
    Chairman & CEO
  • Mr. Michael Liggett B.Sc. (Age 61)
    C.A., C.P.A., CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director
    Comp: $42.45k
  • Dr. Peter Hnik (Age 65)
    Chief Medical Officer & Director

ICO Stock Analysis - Frequently Asked Questions

How have ICO shares performed in 2024?

iCo Therapeutics' stock was trading at C$0.11 at the start of the year. Since then, ICO stock has increased by 0.0% and is now trading at C$0.11.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of iCo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCo Therapeutics investors own include iCo Therapeutics (ICOTF), Theratechnologies (TH), Regulus Therapeutics (RGLS), Nemaska Lithium (NMX), Freeport-McMoRan (FCX), Eldorado Gold (EGO), Dextera Surgical (DXTR), Ag Growth International (AFN), Aurora Cannabis (ACBFF) and

How do I buy shares of iCo Therapeutics?

Shares of ICO stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:ICO) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners